HealthCare Global Enterprises announced its audited annual financial results for the year ended March 31, 2026. The company reported a total income of INR 257,040 Mn for FY26, reflecting a 14% increase compared to INR 225,766 Mn in the previous fiscal year. The net profit for the period attributable to equity shareholders stood at INR 1,376 Mn, while the Adjusted Profit After Tax (PAT) for the full year surged to INR 557 Mn, a 25% increase from INR 444 Mn in FY25.

Operational and Financial Performance

The company's operational metrics showed robust expansion during the fiscal year. Volumes reached 294,912, a 12% increase from the prior year, while Average Realization Per Payor (ARPP) grew to INR 84,261. Adjusted EBITDA for the year stood at INR 4,711 Mn, a 19% year-over-year increase, with the margin expanding by 68 basis points to 18.5%. The West region emerged as a key growth driver, delivering 14% revenue growth, followed by the South and East regions with 13% and 11% growth respectively.

Q4 FY26 Highlights

In the fourth quarter, HealthCare Global Enterprises recorded total income of INR 66,540 Mn. The net profit attributable to equity shareholders for the quarter was INR 217 Mn. Adjusted EBITDA for the quarter increased by 17% to INR 1,252 Mn, with the margin expanding to 19.2% from 18.3% in the same period last year. The Adjusted PAT for the quarter surged to INR 341 Mn from INR 74 Mn in Q4 FY25. The company also recorded an exceptional item of INR 319 Mn in the current quarter.

Strategic Developments

The Board approved the divestment of the company's non-core fertility business, Milann, to Inviga Healthcare Fund I. The transaction values Milann at an enterprise valuation of INR 632 Mn, with an equity consideration of INR 376 Mn payable in two tranches. The deal is expected to close in Q1 FY27, allowing the company to focus capital allocation on its core oncology platform.

Capital Allocation and Expansion

The company completed a rights issue to raise INR 4,250 Mn, which was oversubscribed 1.3 times. Capital expenditure for FY26 totaled INR 2,885 Mn, with significant investments directed towards the North Bangalore facility, which commenced operations bringing MR-LINAC technology to the region. Net debt as of March 31, 2026, stood at INR 3,387 Mn, a significant reduction from INR 6,317 Mn in the previous year, resulting in a net debt to EBITDA ratio of 0.98x.

Future Outlook

Management highlighted the company's path to improving profitability and return on capital, driven by the movement of centres into higher revenue buckets. The growing cohort of centres generating INR 50-100 Mn per month provides a strong foundation for future margin expansion. Additionally, brownfield expansion of over 200 beds is planned over the next 24 months across key locations including Bangalore, Cuttack, Ranchi, Vizag, and Bhavnagar.

HealthCare Global Enterprises Limited has announced a series of key appointments and re-appointments following its Board meeting held on May 19, 2026. The decisions, taken under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, include changes to the Board of Directors, the Chief Financial Officer, and senior management personnel.

Board and Senior Management Changes

The Board approved the re-appointment of Mr. Rajiv Maliwal as a Non-Executive Independent Director for a second term of five consecutive years, effective from May 25, 2026. This re-appointment is subject to the approval of the company's shareholders. Mr. Maliwal shall not be liable to retire by rotation.

In a significant shift in the finance leadership, Mr. Sanjeev Kumar has been appointed as the Chief Financial Officer and Key Managerial Personnel of the company. His appointment is effective from the commencement of business hours on May 25, 2026. Consequently, Dr. Manish Mattoo, who was serving as the Interim Chief Financial Officer, shall cease to hold this position effective from the same date.

New Investor Relations Head

The company has strengthened its investor relations function with the appointment of Mr. Ravi Gothwal as AVP – Investor Relations. He has been designated as a Senior Management Personnel, with his appointment effective immediately from May 19, 2026.

Internal Auditor Re-appointment

The Board also approved the re-appointment of Mr. Vijay S. Shanbhag as the Internal Auditor of the company for a further term of one year. This appointment under Section 138 of the Companies Act, 2013, is effective from May 30, 2026.

Summary of Appointments